Niraparib

Generic Name
Niraparib
Brand Names
Zejula
Drug Type
Small Molecule
Chemical Formula
C19H20N4O
CAS Number
1038915-60-4
Unique Ingredient Identifier
HMC2H89N35
Background

Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, fallopian tube, or primary peritoneal can...

Indication

Niraparib is indicated for the maintenance treatment of adult patients with advanced or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy.
...

Associated Conditions
Advanced Epithelial Ovarian Cancer, Advanced Primary Peritoneal Carcinoma, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer, Advanced Fallopian Tubes Cancer
Associated Therapies
Maintenance therapy
Clinical Trials
Related News

Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer

First Posted Date
2023-01-05
Last Posted Date
2024-11-21
Lead Sponsor
City of Hope Medical Center
Target Recruit Count
45
Registration Number
NCT05672095
Locations
🇺🇸

City of Hope Medical Center, Duarte, California, United States

Reirradiation and Niraparib in Patients With Recurrent Glioblastoma

First Posted Date
2022-12-27
Last Posted Date
2024-03-26
Lead Sponsor
University College, London
Registration Number
NCT05666349

A Chinese Patent Medicine Yangzhengxiaoji Capsule to Improve the Nausea of Niraparib in the Maintenance Treatment in Ovarian Cancer

Phase 2
Not yet recruiting
Conditions
Ovarian Cancer
Interventions
Drug: Yangzheng Xiaoji
Drug: Niraparib
First Posted Date
2022-12-07
Last Posted Date
2022-12-07
Lead Sponsor
Sichuan Cancer Hospital and Research Institute
Target Recruit Count
50
Registration Number
NCT05641506
Locations
🇨🇳

Sicchuan cancer hospital, Chengdu, Sichuan, China

Personalized Medicine for Advanced Biliary Cancer Patients

First Posted Date
2022-11-14
Last Posted Date
2024-11-26
Lead Sponsor
UNICANCER
Target Recruit Count
800
Registration Number
NCT05615818
Locations
🇧🇪

Universitair Ziekenhuis Leuven, Leuven, Belgium

🇫🇷

CHU Amiens Picardie, Amiens, France

🇫🇷

CHU d'Angers, Angers, France

and more 69 locations

Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer

First Posted Date
2022-11-01
Last Posted Date
2024-12-18
Lead Sponsor
Canadian Cancer Trials Group
Target Recruit Count
484
Registration Number
NCT05601440
Locations
🇨🇦

The Jewish General Hospital, Montreal, Quebec, Canada

🇨🇦

Tom Baker Cancer Centre, Calgary, Alberta, Canada

🇨🇦

BCCA - Kelowna, Kelowna, British Columbia, Canada

and more 7 locations

Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma

Phase 2
Recruiting
Conditions
Penile Carcinoma
Interventions
Drug: Dostarlimab
Drug: Niraparib
First Posted Date
2022-09-02
Last Posted Date
2024-11-29
Lead Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Target Recruit Count
25
Registration Number
NCT05526989
Locations
🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

🇺🇸

Moffitt Cancer Center, Tampa, Florida, United States

Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation

First Posted Date
2022-08-31
Last Posted Date
2024-02-15
Lead Sponsor
University of Oklahoma
Target Recruit Count
92
Registration Number
NCT05523440
Locations
🇺🇸

Stephenson Cancer Center, Oklahoma City, Oklahoma, United States

A Study of Niraparib in People With Soft Tissue Sarcoma Who Have Changes in Their Tumor DNA

Phase 2
Active, not recruiting
Conditions
Sarcoma,Soft Tissue
Sarcoma Uterus
Interventions
Drug: Niraparib
First Posted Date
2022-08-25
Last Posted Date
2024-11-05
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
8
Registration Number
NCT05515575
Locations
🇺🇸

Memorial Sloan Kettering Cancer Center (Limited Protocol Activities), Basking Ridge, New Jersey, United States

🇺🇸

Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States

🇺🇸

Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale, New York, United States

and more 4 locations

Phase II Study of Niraparib in Metastatic TNBC Patients With Homologous Recombination Deficiency

First Posted Date
2022-07-18
Last Posted Date
2022-07-18
Lead Sponsor
Zhejiang Cancer Hospital
Target Recruit Count
50
Registration Number
NCT05461690

Niraparib as First Line Therapy With Metastatic Homologous Repair-deficient Pancreatic Cancer

Phase 2
Recruiting
Conditions
Metastatic Pancreatic Cancer
Interventions
Drug: Niraparib
First Posted Date
2022-07-05
Last Posted Date
2023-03-30
Lead Sponsor
Centre Leon Berard
Target Recruit Count
28
Registration Number
NCT05442749
Locations
🇫🇷

Centre Léon Bérard, Lyon, France

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy